Biological agents in psoriatic arthritis
Interleukin-17 inhibition in psoriatic arthritis
T. Boyd1, A. Kavanaugh2
- Western University, London, ON, Canada.
- Division of Rheumatology, Allergy and Immunology, Center for Innovative Therapy (CIT), University of California, La Jolla, CA, USA. akavanaugh@ucsd.edu
CER8879
2015 Vol.33, N°5 ,Suppl.93
PI 0119, PF 0123
Biological agents in psoriatic arthritis
Free to view
(click on article PDF icon to read the article)
PMID: 26471234 [PubMed]
Received: 20/08/2015
Accepted : 20/08/2015
In Press: 15/10/2015
Published: 16/10/2015
Abstract
Greater understanding of the underlying disease process has led to the development of targeted therapeutic agents and innovative strategies in the treatment of psoriatic arthritis (PsA). This report addresses novel medications targeting the T helper 17 cell pathway, specifically those inhibiting interleukin-17A and its receptor, and discusses their role as effective therapies in the management of PsA.
